Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …

Proteins in the Bcl-2 family are central regulators of programmed cell death, and members
that inhibit apoptosis, such as Bcl-XL and Bcl-2, are overexpressed in many cancers and …

The development of effective pharmacological inhibitors of multidomain scaffold proteins,
notably transcription factors, is a particularly challenging problem. In part, this is because …

The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies,
including diffuse large B cell lymphoma (DLBCL). Disruption of its interaction with …

B-cell lymphoma 6 (BCL6) inhibition is a promising mechanism for treating hematological
cancers but high quality chemical probes are necessary to evaluate its therapeutic potential …

In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to
the birth of thousands of children with multiple defects. Despite the teratogenicity of …

B-cell lymphoma extra large (BCL-XL) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as …

Genes that drive the proliferation, survival, invasion and metastasis of malignant cells have
been identified for many human cancers,,–. Independent studies have identified cell death …

The BCL-2 oncogene promotes cancer progression by prohibiting cell death. BCL-2-related
regulators were once thought to constitute a simple, two-class system of anti-death and pro …

Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with
deletion of chromosome 5q (del (5q)). Here, we demonstrate that lenalidomide induces the …